Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 145Stomach Neoplasms 22Triple Negative Breast Neoplasms 21Inflammatory Breast Neoplasms 14Carcinoma, Hepatocellular 13Esophageal Neoplasms 11Lymphoma, Large B-Cell, Diffuse 7Neoplasms 6Pancreatic Neoplasms 5Urinary Bladder Neoplasms 4Adenocarcinoma Of Esophagus 4Testicular Neoplasms 3Sarcoma 3Primary Breast Cancer 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Non-Muscle Invasive Bladder Neoplasms 3Liver Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Ductal, Breast 3Breast Neoplasms, Male 3Unspecified Adult Solid Tumor, Protocol Specific 2Recurrence 2Pathologic Complete Response 2Neoplastic Cells, Circulating 2Neoplasms, Germ Cell and Embryonal 2HER2-negative Breast Cancer 2Carcinoma, Adenoid Cystic 2Breast Diseases 2pCR Rate 1Women With Primary Breast Cancer 1

Interventions

Cyclophosphamide 30N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 21Prednisone 20Etoposide 20Vincristine 16Whole-Body Irradiation 15Doxorubicin 15fludarabine phosphate 14Peripheral Blood Stem Cell Transplantation 14romidepsin 13Mycophenolic Acid 12Lenalidomide 12Gemcitabine 12Cyclosporine 10Azacitidine 10Brentuximab Vedotin 9Bortezomib 9Alemtuzumab 8Dexamethasone 7Methotrexate 6Cytarabine 6Busulfan 6Carmustine 5pembrolizumab 4fludarabine 4Vorinostat 4Tacrolimus 4Rituximab 4Melphalan 4Ifosfamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, T-Cell, Peripheral × Epirubicin × Clear all
NCT04061772 2019-08-20

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

Zhejiang Cancer Hospital

Phase 2 Unknown
54 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡